title: Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat.
abstract: The effect of combination NSAID therapy of tilomisole with aspirin or naproxen was studied in rats with carrageenan-induced paw edema and established adjuvant arthritis. Inflamed paws were measured using mercury plethysmography and the arthritic paws were X-rayed to determine any bony/soft tissue changes. The gastrointestinal tract was also examined for bleeding and ulceration. Tilomisole had a less potent acute anti-inflammatory effect than aspirin or naproxen, but produced no significant gastrointestinal damage. A significant reduction in anti-inflammatory activity was observed with the tilomisole/aspirin combination in acute inflammation. Only additive interactions were observed with the naproxen inhibition. In the established arthritis assay, a significant synergistic anti-inflammatory response, i.e. both inhibition of paw edema and bone erosion, was also observed with the 80 and 93% tilomisole/naproxen combinations. The gastric ulcerogenic effect of the combination paralleled its increased activity. The synergism between tilomisole and naproxen in this chronic arthritic model may be due to enhanced cyclooxygenase inhibitory activity. These drug interaction studies suggest possible interactions in human clinical trials of rheumatoid arthritis.
authors.affiliation: Division of Experimental Therapeutics, Wyeth-Ayerst Research, Princeton, NJ 08543-8000.
authors.forename: W
authors.initials: W
authors.lastname: Calhoun
authors.forename: S C
authors.initials: SC
authors.lastname: Gilman
authors.forename: L J
authors.initials: LJ
authors.lastname: Datko
authors.forename: T W
authors.initials: TW
authors.lastname: Copenhaver
authors.forename: R P
authors.initials: RP
authors.lastname: Carlson
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000188:drug therapy; D001241:Aspirin / Q000494:pharmacology* / Q000633:toxicity; D001562:Benzimidazoles / Q000494:pharmacology* / Q000633:toxicity; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology; D002351:Carrageenan; D003238:Connective Tissue / Q000187:drug effects / Q000473:pathology; D004347:Drug Interactions; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000473:pathology; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D009288:Naproxen / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001562:Benzimidazoles; D009288:Naproxen; C029171:tilomisole; D002351:Carrageenan; D001241:Aspirin